Antitumor efficacy of MUC1-derived variable epitope library treatments in a mouse model of breast cancer.

Abstract

The identification of novel targets for cancer immunotherapy and the development of new vaccine immunogens are subjects of permanent interest. MUC1 is an overexpressed antigen found in most tumors, and its overexpression correlates with poor prognosis. Many attempts to direct the immune response against MUC1 in tumor cells have failed, including several clinical trials. We have previously developed an innovative Variable Epitope Library (VEL) vaccine platform that carries massively substituted mutant variants of defined epitopes or epitope regions as an alternative to using wild-type peptide sequences-based immunogens. Here, two murine MUC1-derived epitopes equivalent to the previously tested in cancer immunotherapy human MUC1 regions were used to generate VELs. We observed that vaccination with the 23L VEL immunogens, encompassing the entire signal peptide region of MUC1, reduces the tumor area compared to the wild-type sequence treatment. Contrastingly, vaccination with the MUC1 signal peptide-derived predicted CD8++ T cell epitope-based VEL, 9MUC1spL, showed similar tumor area reduction as the wild-type treatment; however, a decrease in lung metastasis after 9MUC1spL treatment was observed. In addition, vaccination induced a large pool of CD8+ T cells which recognized most variant epitopes from 9MUC1spL. Also, we generated MUC1 variable number tandem repeat (VNTR)-based VELs that reduced the metastatic burden when dendritic cells and M13 recombinant bacteriophages were used as vaccine carriers. Collectively, our data demonstrate the immunogenic and antitumor properties of MUC1 signal peptide- and VNTR-derived VEL immunogens.

• Authors: Josué Odales, Rodolfo Servín-Blanco, Fernando Martínez-Cortés, Jesus Guzman Valle, Allan Noé Domínguez-Romero, Goar Gevorkian, Karen Manoutcharian
• Journal: Vaccine (Vaccine) Vol. 40 Issue 33 Pg. 4796-4805 (08 05 2022) ISSN: 1873-2518 [Electronic] Netherlands
• PMID: 35788294 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2022 Elsevier Ltd. All rights reserved.

Chemical References

• Cancer Vaccines
• Epitopes, T-Lymphocyte
• MUC1 protein, human
• Mucin-1
• Protein Sorting Signals
• muc1 protein, mouse

Topics

• Animals
• Breast Neoplasms (genetics, therapy)
• CD8-Positive T-Lymphocytes
• Cancer Vaccines
• Disease Models, Animal
• Epitopes, T-Lymphocyte (genetics)
• Female
• Humans
• Mice
• Mucin-1 (genetics)
• Protein Sorting Signals